Family Practice

Total Page:16

File Type:pdf, Size:1020Kb

Family Practice THE JOURNAL OF FAMILY PRACTICE Marifel Mitzi F. Fernandez, MD Performance-enhancing drugs Robert G. Hosey, MD University of Kentucky snare nonathletes, too Primary Care Sports Medicine Fellowship, Lexington [email protected] High school athletes aren’t the only ones seeking an edge. Here are the red fl ags and unexpected drugs to watch for Practice recommendations ercises regularly, has been taking some • Multiple adverse effects, including protein shakes and what he refers to as serious cardiovascular effects, a “natural” supplement. His lab work have prompted bans on the sale of shows some elevation in his aspartate anabolic androgenic® Dowdensteroids (AAS) Healthaminotransferase Media (AST) and alanine and their use in competition (A). aminotransferase (ALT), with a negative hepatitis panel. The rest of his metabolic • Copyright Most users ofFor AAS andpersonal other use panelonly is within normal limits. performance-enhancing drugs are JC was on the track team in high nonathletes or recreational body school, and since graduation has con- builders who begin using these tinued to work out and stay fi t. You ask IN THIS ARTICLE substances in their teen years. him if he takes steroids, and he tells you Ask about steroid or supplement he was warned about the risks of ana- ❚ What’s really in use during yearly physicals (C). bolic androgenic steroids (AAS) in high that supplement? school. He sticks to a “natural” supple- Page 18 Strength of recommendation (SOR) ment, which he buys online or through A Good-quality patient-oriented evidence friends at the gym. Still, you know that ❚ B Inconsistent or limited-quality patient-oriented evidence What to watch for C Consensus, usual practice, opinion, disease-oriented elevated liver enzymes and hypertension Page 19 evidence, case series can be associated with AAS use and that dietary supplements don’t have to meet the same standards the Food and Drug C, a 23-year-old man, is in your Administration (FDA) imposes on drugs. offi ce for evaluation of high blood (See “What’s in that supplement? Labels Jpressure, after failing a commercial don’t always help” on page 18.) You driver’s license exam the previous week. warn him that supplements aren’t always He has been your patient for the past 10 safe, and ask him to bring in his supple- years, and his previous annual physicals ment bottle so you can go over the label have been unremarkable. He is 5'10'' tall, and, possibly, have the contents tested. weighs 209 pounds, and has a muscular build. His blood pressure today is 160/90 and his heart rate is 62 and regular. The ❚ Pursuit of that “edge” rest of his physical exam is normal. extends beyond Olympians He is a nonsmoker, rarely uses al- Even before the start of the modern cohol, and denies illicit drug use. He ex- Olympic games, athletes have used 16 VOL 58, NO 1 / JANUARY 2009 THE JOURNAL OF FAMILY PRACTICE For mass reproduction, content licensing and permissions contact Dowden Health Media. 16_JFP0109 16 12/16/08 12:05:43 PM ergogenic aids—substances used to en- Anabolic androgenic steroids: hance performance, energy, or work Often paired with energy drinks capacity—to give themselves a “com- Teenagers may refer to AAS as “pumpers,” petitive edge.”1,2 Athletes still use these “gym candy,” or “juice.” Trade names for substances today, and they have been AAS are Dianabol, Anadrol, Deca Dura- joined by nonathletes—some of whom bolin, Parabolin, and Winstrol. AAS are simply want to look good. often used with nutritional supplements A 2004 Internet study of AAS us- like creatine, multivitamins, and energy ers reported that the majority are rec- drinks, in the belief that these regimens reational bodybuilders or nonathletes. will make the user stronger, more muscu- Twenty-fi ve percent of participants in lar, and a better athlete.6,7 this survey reported starting using ste- AAS are synthetic analogues of tes- roids during their teenage years.3 tosterone and come in oral, injectable, An ongoing study of high school and transdermal forms.8,9 At supraphysi- students and young adults indicates ologic doses, testosterone has been found an AAS use prevalence rate of 1.1% to to increase lean body (fat-free) mass and 2.3% in boys and 0.4% to 0.6% in girls. muscle strength in humans.10 The anabol- Approximately 40% of survey partici- ic effects are more pronounced when AAS pants noted that obtaining steroids was are used at higher doses over longer pe- relatively easy.4 riods of time, especially when combined The Centers for Disease Control and with a strength training program.9,10 AAS Prevention (CDC) reports that 4.4% to have also been found to stimulate the 5.7% of boys (grades 9 through 12) production of growth hormone and insu- have used illegal steroids and that 1.9% lin-like growth factor and to counteract to 3.8% of girls have.5 the catabolic effects of cortisol.11 Few AAS users tell their physicians The use and possession of AAS with- of their steroid use. Part of the reason, out a doctor’s prescription is illegal in the of course, is that illegal substance use United States. A majority of AAS users is stigmatized and can lead to prosecu- buy their medications through Internet FAST TRACK tion. Another reason, though, is that suppliers, with some of the drugs being The combination these patients think physicians don’t manufactured overseas or in illicit labs.3 know much about these substances.3 Substandard quality control in manu- of high doses Still other patients, like JC, don’t tell facture poses an increased health risk to of caffeine and because they may not even be aware consumers. ephedrine has that some substances billed as “natural” Adverse effects include injection site a potential for conceal potential dangers. pain, acne, baldness, gynecomastia, tes- For help in spotting patients who ticular atrophy, sexual dysfunction, and life-threatening are using these agents, see “Red fl ags psychological disturbances (also known arrhythmia, for performance-enhancing drug use” as “roid rage”).8,9,11-13 Increases in liver hypertension, on page 20. enzymes with the oral forms of AAS have also been noted.8 In the prepubertal and stroke athlete, premature physeal closure may ❚ Performance-enhancing occur, resulting in permanent short stat- drugs go by many names ure.14 Women who take AAS may have Refi ning your care of patients who are virilization effects, menstrual irregulari- taking performance-enhancing drugs re- ties, and early menopause.11 quires that you know the various names The cardiovascular risks of AAS use these drugs go by, the reason your pa- are substantial. High-dose and long-term tients may be taking them, and the ad- AAS use has been linked to cardiomy- verse effects associated with them. This opathy and sudden death.15-20 Some data review, and the TABLE, will help. suggest the development of accelerated www.jfponline.com VOL 58, NO 1 / JANUARY 2009 17 17_JFP0109 17 12/16/08 12:05:47 PM THE JOURNAL OF FAMILY PRACTICE Androstat 100, is a precursor of tes- What’s in that supplement? tosterone. This substance is produced in the adrenal glands and gonads.2 Ini- Labels don’t always help tially marketed as a dietary supplement nder the provisions of the 1994 Dietary Supplement Health and anti-aging drug, it was banned by Uand Education Act (DSHEA), supplement manufacturers, the FDA in 2004 because of its potent 26 not the Food and Drug Administration (FDA), are responsible anabolic and androgenic effects. Er- for guaranteeing the safety of their products.52 Components of gogenic use includes promoting muscle the various supplements available are not uniform, and do not building and strength and fat reduction.2 need to be submitted to the FDA for analysis. A study analyzing Studies on healthy young men found no several nutritional supplements revealed the presence of improvement in skeletal muscle adapta- anabolic androgenic steroids (AAS) (14.8% of 634 products) not tion to resistance training with andro- mentioned in the labeling.53 stenedione supplementation for 8 to 12 Using supplements can result in positive drug tests for weeks.27,28 Studies of its effect on increas- banned substances and unwanted side effects. It is important ing blood testosterone levels are confl ict- to ask about supplement use during annual checkups and ing.27,29 Several studies noted an increase sports physicals—especially if the patient has unexplained high in estradiol levels after oral androstene- blood pressure or other somatic complaints. dione supplementation.9,11,27-29 Endocrine pathways with this drug are similar to AAS, and the side effect atherosclerosis with AAS use, leading to profi le is similar as well, although not as hypertension, coronary artery disease pronounced. Larger, long-term studies (CAD), and acute myocardial infarc- are needed to fi ll out this drug’s profi le tion.15,16,18-21 An unfavorable lipid panel and document its effects on the athletes has also been noted, with an increase in who use it. LDL and decreased HDL.18-21 Dehydroepiandrosterone: Tetrahydrogestrinone: Marketed as a “wonder drug” FAST TRACK A “designer” steroid Dehydroepiandrosterone (DHEA), mar- A study analyzing Tetrahydrogestrinone (THG) was ini- keted under the names Prastera, Fidelin, tially developed to avoid detection by and Fluasterone, is another precursor of several nutritional testing protocols current at the time.22-24 testosterone. It is produced in the adrenal supplements This drug has garnered signifi cant media cortex and has weak androgenic proper- revealed the attention in the past few years because ties.2 DHEA is a dietary supplement mar- presence of of scandals involving professional and keted as a “wonder drug” and, like an- Olympic athletes.
Recommended publications
  • 16A-Fluoro-5-Androsten-17-0Ne
    MILITARY MEDICINE, 167, Suppl. 1:060,2002 Inhibition of Adjuvant-Induced Arthritis by 16a-Fluoro-5-Androsten-17-0ne Guarantor: Arthur G. Schwartz, PhD Contributors: Arthur G. Schwartz, PhD; Laura L. Pashko, PhD The adrenal steroid dehydroepiandrosterone (DHEA) produces tant receptor and that inhibition ofthis enzyme by DHEA me­ cancer-preventive, antiatherosclerotic, antidiabetic, Immuno­ diates some of the biological effects of the steroid. DHEA is a modulating, and anti-inflammatory effects in laboratory ani­ potent uncompetitive inhibitor of G6PDH, the rate-controlling mals. The clinical use of DHEAis limited by its androgenicity. Downloaded from https://academic.oup.com/milmed/article/167/suppl_1/60/4820113 by guest on 01 October 2021 enzyme in thepentose phosphate pathway, 10 and it appearsthat Wehave developed a synthetic congener ofDHEAcalled fluaster­ the antiproliferative and antitumor-promoting effects of the one that, in animal tests, lacks the androgenicity, estrogenicity, and peroxisome-proliferating effects of DHEA but retains the DHEA class of steroids is mediated through inhibition of cancer-preventive, antidiabetic, and anti-inflammatory efficacy. G6PDH.1,11,12 Two important metabolic consequences ofG6PDH This report discusses how fluasterone ameliorates the develop­ inhibition are a lowering ofNADPH-reducing equivalents avail­ ment of joint inflammation in an adjuvant-arthritis model in able forbiosynthetic processes, including ribo- and deoxyribo­ Lewis rats. nucleotide synthesis, and a reduction in ribose-5-phosphate,
    [Show full text]
  • Cyclodextrins As Drug Carrier Molecule: a Review
    Sci Pharm www.scipharm.at Review Open Access Cyclodextrins as Drug Carrier Molecule: A Review ARUN RASHEED *, ASHOK KUMAR C. K., SRAVANTHI V. V. N. S. S. Department of Pharmaceutical Chemistry, Sree Vidyanikethan College of Pharmacy, Sri Sainath Nagar, Tirupati, Andhra Pradesh, India-517502 * Corresponding author. E-mail: [email protected] (R. Arun) Sci Pharm. 2008; 76: 567–598 doi:10.3797/scipharm.0808-05 Published: November 1st 2008 Received: August 5th 2008 Accepted: October 31st 2008 This article is available from: http://dx.doi.org/10.3797/scipharm.0808-05 © Arun et al; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract The cyclodextrins have a wide range of applications in different areas of drug delivery and pharmaceutical industry due to their complexation ability and other versatile characteristics. The most common pharmaceutical application of cyclodextrin is to enhance the solubility, stability, safety and bioavailability of drug molecules. The purpose of this review is to discuss and summarize some of the findings and applications of cyclodextrin (CD) and their derivatives in different areas of drug delivery. This article highlights the molecular structure, properties like complexation, solubility etc. of cyclodextrins and focuses on its use for parenteral, oral, ophthalmic and nasal drug delivery. Other routes including dermal, rectal, sublingual and pulmonary delivery are also briefly addressed. The objective of this contribution is to focus on the potential use of chemically modified cyclodextrins as high-performance drug carriers in drug delivery systems with emphasis on the more recent developments.
    [Show full text]
  • An Orally Bioavailable Synthetic Analog of an Active Dehydroepiandrosterone Metabolite Reduces Established Disease in Rodent Models of Rheumatoid Arthritis
    0022-3565/09/3293-1100–1109$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 329, No. 3 Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics 145086/3474987 JPET 329:1100–1109, 2009 Printed in U.S.A. An Orally Bioavailable Synthetic Analog of an Active Dehydroepiandrosterone Metabolite Reduces Established Disease in Rodent Models of Rheumatoid Arthritis Halina Offner, Gary S. Firestein, David L. Boyle, Raymond Pieters, James M. Frincke, Armando Garsd, Steven K. White, Christopher L. Reading, and Dominick L. Auci Department of Neurology, Oregon Health and Science University, Portland, Oregon (H.O.); Institute for Risk Assessment Sciences-Immunotoxicology, Utrecht University, Utrecht, The Netherlands (R.P.); Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, California (D.L.B., G.S.F.); and Hollis-Eden Pharmaceuticals Inc., San Diego, California (J.M.F., A.G., S.K.W., C.L.R., D.L.A.) Downloaded from Received August 20, 2008; accepted March 17, 2009 ABSTRACT Dehydroepiandrosterone (DHEA) treatment provides diverse anti- even when treatments were delayed until 7 days after the onset jpet.aspetjournals.org inflammatory benefits in rodent models of diseases, including of arthritis. Furthermore, dose-dependent benefit was observed rheumatoid arthritis (RA), but only limited benefits to patients. In in the DBA mouse model of collagen antibody-induced arthritis, rodents, DHEA is metabolized to (among others) androstene- as well as reductions in IL-6 and matrix metalloproteinase-3 3␤,7␤,17␤-triol (AET), which retains potent anti-inflammatory mRNA levels in joints at the peak of disease and at the end of activity.
    [Show full text]
  • Inhibition of Carcinogen-Activating Enzymes by 16␣-Fluoro-5-Androsten-17-One
    [CANCER RESEARCH 62, 3685–3690, July 1, 2002] Inhibition of Carcinogen-activating Enzymes by 16␣-Fluoro-5-androsten-17-one Henry P. Ciolino,1 Christopher J. MacDonald, and Grace Chao Yeh Cellular Defense and Carcinogenesis Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, Maryland 21702- 1201 ABSTRACT decrease in the incidence of a number of different types of cancer in humans (5, 6). In animal models, DHEA has been shown to inhibit In the present study, we examined the effect of a synthetic analogue of both spontaneous and chemically induced carcinogenesis in rodents the chemopreventive hormone dehydroepiandrosterone, 16␣-fluoro-5- (7–9). Specifically, DHEA inhibits both skin and mammary tumori- androsten-17-one, also known as fluasterone, on the activity and expres- sion of carcinogen-activating enzymes in MCF-7 cells. The increase in genesis caused by the PAH DMBA (10–13). DHEA has been shown cytochrome P450 (CYP) 1A1 and 1B1 activity, as measured by to inhibit DMBA activation in vitro (14) and DMBA-DNA binding in ethoxyresorufin-O-deethylase activity, in cells treated with the carcino- vivo (15–18). The dramatic decline of DHEA levels in humans with gens dimethylbenzanthracene (DMBA) or 2,3,5,7-tetrachlorodibenzo-p- advancing age is, therefore, of substantial concern. However, DHEA dioxin (TCDD), was inhibited by cotreatment with fluasterone. However, supplementation is problematic, because it can be converted to both treatment of the cells with fluasterone after induction with DMBA or testosterone and estrone (19), and it exhibits considerable liver tox- TCDD failed to decrease enzyme activity, indicating that inhibition was icity (20) and hepatocarcinogenicity (21).
    [Show full text]
  • Metabolism, Alcohol and Toxicity About These Slides
    Best of ILC 2019 Metabolism, alcohol and toxicity About these slides • These slides provide highlights of new data presented at the International Liver Congress 2019 • Please feel free to use, adapt, and share these slides for your own personal use; however, please acknowledge EASL as the source • Definitions of all abbreviations shown in these slides, and a full copy of the original abstract text, are provided within the slide notes • Submitted abstracts are included in the slide notes, but data may not be identical to the final presented data shown on the slides These slides are intended for use as an educational resource and should not be used to make patient management decisions. All information included should be verified before treating patients or using any therapies described in these materials Contents 1. NAFLD: Clinical aspects except therapy LB-01 Double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension GS-08 The prevalence of non-alcoholic fatty liver disease in young adults: An impending public health crisis? PS-061 NAFLD/NASH patients with AdvLD have high comorbidity burden, HCRU and costs: results from Italian administrative databases PS-203 Dietary risk factors for non-alcoholic fatty liver disease by cirrhosis status: The US multiethnic cohort LBP-01 In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: Follow-up of population surveys Click here to skip to this section 2. NAFLD: Therapy GS-01 Efficacy, safety,
    [Show full text]
  • Dehydroepiandrosterone Biosynthesis, Role, and Mechanism of Action in the Developing Neural Tube
    CORE Metadata, citation and similar papers at core.ac.uk ORIGINAL RESEARCH ARTICLE Provided by PubMed Central published: 07 February 2012 doi: 10.3389/fendo.2012.00016 Dehydroepiandrosterone biosynthesis, role, and mechanism of action in the developing neural tube Mark Galdo, Jennifer Gregonis, Christelle S. Fiore and Nathalie A. Compagnone* Laboratory for Spinal Cord Development and Regeneration, Department of Neurological Surgery, University of California, San Francisco, CA, USA Edited by: Dehydroepiandrosterone (DHEA) is synthesized from cholesterol by activity of P450scc Kazuyoshi Tsutsui, Waseda University, and P450c17, enzymes that we previously characterized in the developing nervous sys- Japan tem. We describe the localization of P450c17 in the differentiated field of the ventral spinal Reviewed by: Synthia H. Mellon, University of cord in different motor neuron subtypes. We show that, during organogenesis, P450c17 California San Francisco, USA activity is regulated along the antero/posterior axis of the spinal cord concomitantly with Ishwar Parhar, Monash University, the gradient of neurogenesis. To examine whether DHEA may modulate this process, Malaysia we measured proliferation and differentiation of ventral neural precursors in primary and *Correspondence: explant cultures. Our results showed that DHEA-induced the expression of class II pro- Nathalie A. Compagnone, Innovative Concepts in Drug Development, tein Nkx6.1, motor neuron precursor Olig-2, and definitive motor neuron marker Isl-1/2. Innovation Park Michel Caucik, BP2 DHEA also promoted proliferation of ventrally committed precursors in isolated spinal cord 100 rte des houilleres, 13590 precursor cultures and in whole spinal cord explants. Both the proliferative and inductive Meyreuil, France. effects of DHEA were dependent on sonic hedgehog signaling.
    [Show full text]
  • Neurosteroids As Regulators of Neuroinflammation
    Frontiers in Neuroendocrinology 55 (2019) 100788 Contents lists available at ScienceDirect Frontiers in Neuroendocrinology journal homepage: www.elsevier.com/locate/yfrne Neurosteroids as regulators of neuroinflammation T Canelif Yilmaza,1, Kanelina Karalib,c,1, Georgia Fodelianakia, Achille Gravanisb,c, ⁎ Triantafyllos Chavakisa,d, Ioannis Charalampopoulosb,c, Vasileia Ismini Alexakia, a Institute of Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany b Department of Pharmacology, Medical School, University of Crete, Heraklion, Greece c Institute of Molecular Biology & Biotechnology, Foundation of Research & Technology-Hellas, Heraklion, Greece d Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK ARTICLE INFO ABSTRACT Keywords: Neuroinflammation is a physiological protective response in the context of infection and injury. However, Neurosteroids neuroinflammation, especially if chronic, may also drive neurodegeneration. Neurodegenerative diseases, such Estrogens as multiple sclerosis (MS), Alzheimer’s disease (AD), Parkinson’s disease (PD) and traumatic brain injury (TBI), β 17 -estradiol display inflammatory activation of microglia and astrocytes. Intriguingly, the central nervous system (CNS) is a Progestogens highly steroidogenic environment synthesizing steroids de novo, as well as metabolizing steroids deriving from Progesterone the circulation. Neurosteroid synthesis can be substantially affected by neuroinflammation,
    [Show full text]
  • Full Text In
    Return to October 2000 Table of Contents ORIGINAL ARTICLE Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers Michael Davidson, MD Drs. Davidson and Maki are with the Chicago Center for Ashok Marwah, PhD Clinical Research, Chicago, Ill.; Drs. A. Marwah, P. Marwah and Lardy are with the Institute for Enzyme Ronald J. Sawchuk, PhD Research and Department of Biochemistry, University of Kevin Maki, PhD Wisconsin, Madison, Wisc.; Dr. Sawchuk is with the Department of Pharmaceutics, College of Pharmacy, Padma Marwah, PhD University of Minnesota, Minneapolis, Minn.; and Dr. Charles Weeks, PhD Weeks is with Humanetics Corp., Chanhassen, Minn. Henry Lardy, PhD Medical subject headings: dehydroepiandrosterone sulfate; pharmacokinetics; prasterone; randomized controlled trials; steroids (Original manuscript submitted Apr. 17, 2000; received in revised form July 10, 2000 accepted July 10, 2000) Clin Invest Med 2000;23(5):300-10. © 2000 Canadian Medical Association Abstract the normal range. No changes in vital signs, blood chem- istry or urinalysis occurred during treatment with 3ß- Objectives: To evaluate the safety and pharmacokinetics acetyl-7-oxo-DHEA compared to placebo. The adminis- of 3-acetyl-7-oxo-DHEA (3ß-acetoxyandrost-5-ene- tered steroid was not detected in the blood but was rapid- 7,17-dione) given orally. ly converted to 7-oxo-DHEA-S, the concentrations of Design: A randomized, double blind, placebo-controlled, which were proportional to dose. This steroid sulfate did escalating dose study. not accumulate; plasma concentrations 12 hours after the Setting: The Chicago Center for Clinical Research. 3ß-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 Participants: Twenty-two healthy men.
    [Show full text]
  • ( 12 ) United States Patent
    US010292951B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,292 , 951 B2 Glick et al. (45 ) Date of Patent: May 21, 2019 ( 54 ) METHODS AND COMPOSITIONS FOR (58 ) Field of Classification Search TREATING CONDITIONS ASSOCIATED CPC . .. .. .. .. A61K 31 / 167 WITH AN ABNORMAL INFLAMMATORY See application file for complete search history . RESPONSES (56 ) References Cited (71 ) Applicant: First Wave Bio , Inc ., Ann Arbor, MI U . S . PATENT DOCUMENTS (US ) 3 , 079 ,297 A 2 / 1963 Schraufstatter et al. (72 ) Inventors : Gary D . Glick , Ann Arbor, MI (US ) ; 5 ,663 , 155 A * 9 / 1997 McCaffrey .. A61K 31/ 70 Luigi Franchi, Ann Arbor, MI (US ) ; 514 / 45 Giancarlo Santus, Milan ( IT ) ( Continued ) ( 73 ) Assignee : First Wave Bio , Inc ., Ann Arbor , MI FOREIGN PATENT DOCUMENTS (US ) CN 105063018 A * 11 / 2015 ( * ) Notice : Subject to any disclaimer, the term of this EP 0938338 9 /2009 patent is extended or adjusted under 35 (Continued ) U . S . C . 154 (b ) by 0 days . OTHER PUBLICATIONS (21 ) Appl . No. : 15 /255 , 102 CureZone .org ( http : / /www . curezone .org / forums/ fm .asp ? i = ( 22 ) Filed : Sep . 1 , 2016 2146880 # i, accessed May 15 , 2017, dated Feb . 2 , 2014 ). * (Continued ) (65 ) Prior Publication Data Primary Examiner — Benjamin J Packard US 2017 /0056347 A1 Mar. 2 , 2017 ( 74 ) Attorney , Agent, or Firm — Fish & Richardson P . C . (57 ) ABSTRACT This disclosure features chemical entities ( e . g ., a compound Related U . S . Application Data exhibiting activity as a mitochondrial uncoupling agent or a (60 ) Provisional application No . 62/ 213 ,016 , filed on Sep . pharmaceutically acceptable salt and / or hydrate and /or coc 1 , 2015 , provisional application No .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0035784 A1 Lancaster Et Al
    US 20170035784A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0035784 A1 Lancaster et al. (43) Pub. Date: Feb. 9, 2017 (54) COMPOSITIONS OF OBETICHOLIC ACID (22) Filed: Apr. 26, 2016 AND METHODS OF USE Related U.S. Application Data (71) Applicants: Intercept Pharmaceuticals, Inc., New York, NY (US); Sumitomo Dainippon (60) Provisional application No. 62/153,040, filed on Apr. Pharma Co., Ltd., Osaka (JP) 27, 2015, provisional application No. 62/317,933, filed on Apr. 4, 2016. (72) Inventors: Richard Gail Lancaster, San Diego, CA (US); Kay K. Olmstead, Publication Classification Escondido, CA (US); Masashi Kagihiro, Osaka (JP); Mitsuhiro (51) Int. Cl. Matono, Osaka (JP); Ikuko Taoka, A 6LX 3/575 (2006.01) Osaka (JP); Mark Pruzanski, New A6II 45/06 (2006.01) York, NY (US); David Shapiro, A69/20 (2006.01) Rancho Sante Fe, CA (US); Roya (52) U.S. Cl. Hooshmand-Rad, San Diego, CA (US); CPC ........... A61K3I/575 (2013.01); A61K 9/2059 Richard Pencek, San Diego, CA (US); (2013.01); A61 K9/2054 (2013.01); A61 K Cathi Sciacca, San Diego, CA (US); 45/06 (2013.01); A61K 9/2072 (2013.01) Lise Eliot, San Diego, CA (US); Jeffrey Edwards, San Diego, CA (US); (57) ABSTRACT Leigh A. MacConell, Encinitas, CA (US); Tonya K. Marmon, San Diego, The disclosure relates to obeticholic acid formulations with CA (US) improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various (21) Appl. No.: 15/139,138 diseases and conditions. Patent Application Publication Feb. 9, 2017.
    [Show full text]
  • Hormone Epimers Regulate Er Stress and Core Regulatory Genes: Network Analysis with Applications to Glioma and Chronic Pressure Ulcers
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2013 HORMONE EPIMERS REGULATE ER STRESS AND CORE REGULATORY GENES: NETWORK ANALYSIS WITH APPLICATIONS TO GLIOMA AND CHRONIC PRESSURE ULCERS Thomas L. Shaak Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Life Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/531 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ©THOMAS L. SHAAK 2013 All Rights Reserved HORMONE EPIMERS REGULATE ER STRESS AND CORE REGULATORY GENES: NETWORK ANALYSIS WITH APPLICATIONS TO GLIOMA AND CHRONIC PRESSURE ULCERS A Dissertation submitted in partial fulfillment of the requirements for the degree Doctor of Philosophy at Virginia Commonwealth University by THOMAS L. SHAAK, LtCol, USAF, BSC B.S. Microbiology, Pennsylvania State University, 1990 M.S. Health Systems Administration, University of Medicine and Dentistry of New Jersey, 2003 M.S. Integrated Life Science, Medical University of South Carolina, 2005 Director: Dr. Robert F. Diegelmann, PhD., Professor of Biochemistry Virginia Commonwealth University Richmond, Virginia August 2013 ACKNOWLEDGEMENT The author would like to thank several people and without them I do not think I would be here now. First, Dr. Douglas Wear, Dr. Mina Izadjoo, PhD., Dr. Sue Cross, PhD, Dr. Mohammed Alavi, PhD, Dr. Hyung Kim, DVM, PhD. all of whom inspired me when I thought I was beyond inspiration.
    [Show full text]
  • Wo 2007/044693 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 19 April 2007 (19.04.2007) WO 2007/044693 A2 (51) International Patent Classification: Tuscaloosa, AL 35401 (US). SWATLOSKI, Richard, P. A61K 31/555 (2006.01) A61K 31/28 (2006.01) [US/US]; 1801 Waterford Lane, Tuscaloosa, AL 35405 (21) International Application Number: (US). HOUGH, Whitney, L. [US/US]; 226 Wolf Creek PCT/US2006/039454 Drive, Albertville, AL 35951 (US). DAVIS, James, Hillard [US/US]; 324 Vanderbilt Drive, Mobile, AL (22) 10 October 2006 (10.10.2006) International Filing Date: 36608 (US). SMIGLAK, Marcin [PL/US]; 3302 Sixth (25) Filing Language: English Avenue East, Apt. C, Tuscaloosa, AL 35405 (US). PER- (26) Publication Language: English NAK, Juliusz [PL/PL]; UL. Nalkowskiej, 8A, PL-60-573 Poznan (PL). SPEAR, Scott, K. [US/US]; 302 County (30) Priority Data: Road 49, Bankston, AL 35542 (US). 60/724,604 7 October 2005 (07.10.2005) US 60/724,605 7 October 2005 (07.10.2005) US (74) Agents: KATZ, Mitchell, A. et al.; Needle & Rosenberg, 60/764,850 2 February 2006 (02.02.2006) US PC, Suite 1000, 999 Peachtree Street, Atlanta, GA 30309- (71) Applicant (for all designated States except US): THE 3915 (US). UNIVERSITY OF ALABAMA [US/US]; 222 Rose (81) Designated States (unless otherwise indicated, for every Administration Building, Post Office Box 870106, kind of national protection available): AE, AG, AL, AM, Tuscaloosa, AL 35487-0106 (US). AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, (72) Inventors; and CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, (75) Inventors/Applicants (for US only): ROGERS, Robin, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, D.
    [Show full text]